How to buy Aligos Therapeutics stock (Aligos Therapeutics)

Aligos Therapeutics is a biotechnology business based in the US. Aligos Therapeutics shares (ALGS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $39.34 – an increase of 19.18% over the previous week. Aligos Therapeutics employs 68 staff and has a trailing 12-month revenue of around $6 million.

Our top picks for where to buy Aligos Therapeutics Inc stock

Buy Aligos Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aligos Therapeutics stock price (NASDAQ: ALGS)

Use our graph to track the performance of ALGS stocks over time.

Aligos Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$39.34
52-week range	$6.76 - $38.30
50-day moving average more info button	$16.83
200-day moving average more info button	$16.03
Wall St. target price	$103.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-7.25

Is it a good time to buy Aligos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aligos Therapeutics price performance over time

Historical closes compared with the close of $38.85 from 2024-12-23

1 week (2024-12-18)	17.69%
1 month (2024-11-25)	89.88%
3 months (2024-09-25)	372.63%
6 months (2024-06-25)	9,540.20%

1 year (2023-12-22)	5,450.00%
2 years (2022-12-23)	70.77%
3 years (2021-12-23)	296.5
5 years (2019-12-21)	N/A

Aligos Therapeutics financials

Revenue TTM	$6 million
Gross profit TTM	$-71,170,000
Return on assets TTM	-67.32%
Return on equity TTM	-146.69%
Profit margin	0%
Book value	$15.07
Market Capitalization more info button	$118.4 million

TTM: trailing 12 months

Aligos Therapeutics share dividends

We're not expecting Aligos Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (3.4% forward annual dividend yield)

Have Aligos Therapeutics's shares ever split?

Aligos Therapeutics's shares were split on a 1:25 basis on 18 August 2024 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aligos Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Aligos Therapeutics shares which in turn could have impacted Aligos Therapeutics's share price.

Aligos Therapeutics share price volatility

Over the last 12 months, Aligos Therapeutics's shares have ranged in value from as little as $6.76 up to $38.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aligos Therapeutics's is 2.116. This would suggest that Aligos Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Aligos Therapeutics's beta into context you can compare it against those of similar companies.

• Novavax (NVAX.US): 2.088
• Gilead Sciences (GILD.US): 0.192
• BioCryst Pharmaceuticals (BCRX.US): 1.887

Aligos Therapeutics overview

Aligos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co. , Ltd.

Frequently asked questions

null
What percentage of Aligos Therapeutics is owned by insiders or institutions?
Currently 17.799% of Aligos Therapeutics shares are held by insiders and 48.86% by institutions. How many people work for Aligos Therapeutics?
Latest data suggests 68 work at Aligos Therapeutics. When does the fiscal year end for Aligos Therapeutics?
Aligos Therapeutics's fiscal year ends in December. Where is Aligos Therapeutics based?
Aligos Therapeutics's address is: One Corporate Drive, South San Francisco, CA, United States, 94080 What is Aligos Therapeutics's ISIN number?
Aligos Therapeutics's international securities identification number is: US01626L1052